Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate

NCT ID: NCT01080716

Last Updated: 2018-11-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-05-31
• Study Completion Date: 2011-12-31

Brief Summary

This study is an inpatient trial to determine the safety, immunogenicity and efficacy of the WRSS1 candidate vaccine in healthy Thai adult volunteers.

Detailed Description

This study is designed as 2 parts.

• Part 1 is a blinded, placebo-controlled inpatient trial in a total of 20 volunteers (14 vaccinees and 6 controls) to determine the safety and immunogenicity. Volunteers will be vaccinated with a single oral dose of 104 colony forming unit (cfu) of WRSS1 or placebo given with bicarbonate buffer.
• Part 2 will be started approximately 60 days after WRSS1 vaccination. This part is an inpatient phase II efficacy trial involving a challenge with the S.sonnei 53G of 10 vaccinees from the first part and 10 naïve controls.

Conditions

Dysentery; Shigella; Diarrhea

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Part 1/Arm 1 of Study: WRSS1 vaccine

WRSS1 is a live attenuated S. sonnei vaccine candidate derived from the Mosely strain of S.sonnei

Group Type: EXPERIMENTAL

Part 1/Arm 1 of Study: WRSS1 vaccine

Intervention Type: BIOLOGICAL

Single, oral dose of WRSS1

Part 1/Arm 2 of Study: Placebo vaccine

Placebo

Group Type: PLACEBO_COMPARATOR

Part 1/Arm 2 of Study: Placebo vaccine

Intervention Type: BIOLOGICAL

Placebo vaccine

Part 2/Arm 1 of Study: S. sonnei 53G

10 volunteers from Study Arm 1/Part 1 (WRSS1 vaccine) plus 4 alternates from Arm 1/Part 1 are given 53G S. sonnei

Group Type: EXPERIMENTAL

Part 2/Arm 1 of Study: S. sonnei 53G

Intervention Type: BIOLOGICAL

Subject from Part 1/Arm 1 of Study are given 53G S. sonnei

Part 2/Arm 2 of Study: S sonnei 53G

10 subjects (naïve controls) plus 4 alternates are give 53G S sonnei

Group Type: ACTIVE_COMPARATOR

Part 2/Arm 2 of Study: S. sonnei 53G

Intervention Type: BIOLOGICAL

10 naïve controls are given S. sonnei 53G

Interventions

Part 1/Arm 1 of Study: WRSS1 vaccine

Single, oral dose of WRSS1

Intervention Type: BIOLOGICAL

Part 1/Arm 2 of Study: Placebo vaccine

Placebo vaccine

Intervention Type: BIOLOGICAL

Part 2/Arm 1 of Study: S. sonnei 53G

Subject from Part 1/Arm 1 of Study are given 53G S. sonnei

Intervention Type: BIOLOGICAL

Part 2/Arm 2 of Study: S. sonnei 53G

10 naïve controls are given S. sonnei 53G

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. 20-40 years old; male or female;

2. General good health as determined by a screening evaluation no greater than 30 days before admission;

3. Normal bowel habits (grade 1-2 stools - no more than one to two stools per day with at least one stool per 2 days;

4. Sexually active females willing to use birth control (birth control pills, injection hormonal contraceptive, implant hormonal contraceptive, hormonal patch, IUD, sterilization for effective contraceptive methods, spermicidal products and barrier methods are considered acceptable)during the entire study (starting from study day -30) and for 3 months after completion of the study (approximately a total of 6 months) or sexually inactive females (no sexual contact). Volunteers who take birth control pills will be required to use additional contraceptive methods for the remaining days of the cycle after discharge from the VTC (alteration of gastrointestinal functions from the oral vaccine or challenge strain may lead to unpredictable efficacy of pills);

5. Will be available and willing to continue participation in the second part of the study if he/she has been randomly selected;

6. Pass the Assessment of Understanding of the consent form.

Exclusion Criteria

1. An acute or chronic medical condition or a clinically significant abnormality on physical exam that, in the opinion of the investigator, would render vaccination or challenge as unsafe;

2. Current use of iron or zinc supplements within the past 7 days; current use of antacids (H2 blockers, omeprazole, OTC agents) or immunosuppressive drug;

3. Unwillingness to follow the study procedures

4. Currently breastfeeding, pregnant (βHCG +) or planning to become pregnant within 3 months after the completion of the study;

5. Allergy to quinolone, sulfa, and penicillin classes of antibiotics;

6. History of any of the following conditions within the past 10 years:

• Arthritis (two or more episodes of joint pain and swelling),
• Gastrointestinal disease (diagnosed by a doctor as having irritable bowel disease, Crohn's disease, ulcerative colitis (biopsy confirmed), celiac disease, stomach or intestinal ulcers), or
• Dyspepsia (digestion or heartburn requiring medication more than once per week);

7. Lifetime previous history of known/suspected Shigella diarrhea (except for volunteers who receive vaccines from Part 1) ;

8. Lifetime history of, or active gallbladder disease;

9. HLA B27 Ag (+); Anti-HIV (+); HBsAg(+); Anti HCV IgG Ab(+); abnormal screening tests judged to be clinically significant as judged by PI or sub-PI (Values are out of the acceptable abnormal range from the table in the protocol) other than mild anemia in females (Hct = 0.33-0.36);

10. Lifetime history of participation in Shigella study (except for volunteers who receive vaccines from Part 1);

11. Concurrent participation in another experimental vaccine or drug study within the past 30 days(except for volunteers who receive vaccines from part1);

12. Serological positive for Shigella sonnei: anti-Shigella sonnei LPS IgG antibody titer in serum >800 (except for volunteers who receive vaccines from Part 1);

13. Receipt of antimicrobial drugs for any reason or acute illness or fever >=38 oC within 7 days before vaccination or challenge;

14. Individuals with household contacts that are immunocompromised;

15. History of major abdominal surgery or laparotomy for any reason in the past 3 years, or abdominal scar of unclear origin;

16. Presence of significant ova or parasite or Shigella bacteria in the stool;

17. Receipt of any of the following (does not include the WRSS1 vaccine):

• a licensed live, attenuated vaccine within the 30 days of challenge
• a licensed subunit or killed vaccine within the 14 days of the challenge
• a blood product, including immunoglobulin, in the 90 days before the challenge

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Mahidol University

OTHER

Sponsor Role: collaborator

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

U.S. Army Medical Research and Development Command

FED

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ladaporn Bodhidatta, MD

Role: STUDY_DIRECTOR

Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences

Punnee Pitisuttithum, MBBS

Role: PRINCIPAL_INVESTIGATOR

Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University

Carl Mason, MD

Role: STUDY_DIRECTOR

Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences

Locations

Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University

Bangkok, , Thailand

Countries

Thailand

References

Pitisuttithum P, Islam D, Chamnanchanunt S, Ruamsap N, Khantapura P, Kaewkungwal J, Kittitrakul C, Luvira V, Dhitavat J, Venkatesan MM, Mason CJ, Bodhidatta L. Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults. Clin Vaccine Immunol. 2016 Jul 5;23(7):564-75. doi: 10.1128/CVI.00665-15. Print 2016 Jul.

Reference Type: DERIVED

PMID: 27146000 (View on PubMed)

Other Identifiers

09-0021

Identifier Type: OTHER

Identifier Source: secondary_id

1609

Identifier Type: OTHER

Identifier Source: secondary_id

A-15647

Identifier Type: -

Identifier Source: org_study_id